ASCO 2023 | Current perspectives from clinical trials using PARP inhibitors for prostate cancer

David James VanderWeele, MD, PhD, Feinberg School of Medicine, Chicago, IL, discusses current trials involving PARP inhibitors for genitourinary cancer. The Phase III TALAPRO-2 trial (NCT03395197) comparing talazoparib plus enzalutamide versus enzalutamide in patients with metastatic castration resistant prostate cancer (mCRPC) showed promising results. However, the deficiencies outside of the trial should be noted. The Phase II BRCAAWAY trial (NCT03012321) is a small cohort study evaluating combination versus sequential monotherapy specifically. The Phase III CASPER trial (NCT04455750) is researching the benefit of adding rucaparib to enzalutamide, and could be important in researching if this combination treatment is beneficial for patients. In trials where access to PARP inhibitors is limited due to financial constraints or where disease has progressed, the comparative efficacy of carboplatin could be studied. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.